DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7) Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Diagnosis and staging of tumors expressing somatostatin receptors.

DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7) Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Nantong Guangyuan Chemicl Co,Ltd	+undefined17712220823	admin@guyunchem.com	China	615	58
Adachibio Inc.	+8108027837258	sales@adachibio.com	Japan	992	58
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
career henan chemical co	+86-0371-86658258 +8613203830695	sales@coreychem.com	China	29856	58
Shenzhen Nexconn Pharmatechs Ltd	+86-755-89396905 +86-15013857715	admin@nexconn.com	China	10406	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19552	58
Beijing Yibai Biotechnology Co., Ltd	0086-182-6772-3597	sales04@yibaibiotech.com	CHINA	419	58
Hebei Yanxi Chemical Co., Ltd.	+8617531153977	allison@yan-xi.com	China	5853	58
TargetMol Chemicals Inc.	+17819995354	marketing@targetmol.com	United States	32281	58
Wuhan Fortuna Chemical Co., Ltd	+86-027-59207850 +86-13986145403;	info@fortunachem.com	China	5972	58

204318-14-9()Verwandte Suche:

---

• DOTA-[TYR3]-OCTREOTIDE
• DOTATOC
• DOTA-FCYWKTCT-OL (DISULFIDE BRIDGE: 2-7)
• DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7)
• [DOTA-DPHE1, TYR3]OCTREOTIDE
• DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THREONINOL
• EDOTREOTIDE
• 4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZA-CYCLODODECAN-1-YL-ACETYL-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-L-THREONINOL, (DISULFIDE BOND)
• DOTA-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Threoninol (Disulfide bridge Cys2-Cys7)
• EDOTREOTIDUM
• L-Cysteinamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-Lthreonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2)-disulfide
• DOTA-TOC204318-14-9
• 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
• DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7)DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7)
• L-Cysteinamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide
• SMT 487
• SMT487
• SMT-487
• somatostatin,DOTATOC,Edotreotide,inhibit,cancer,Inhibitor,radionuclides,SDZ-SMT 487
• DOTA-(Tyr3)-Octreotide acetate salt
• DOTA-(Tyr?)-Octreotide acetate salt
• NOTA-TOC
• DOTA-[Tyr3]Octreotide, DOTA-TOC, Edotreotide
• 204318-14-9
• C65H92N14O18S2
• peptide